<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431093</url>
  </required_header>
  <id_info>
    <org_study_id>P06673</org_study_id>
    <secondary_id>C-1755</secondary_id>
    <nct_id>NCT00431093</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol/Noresterone (Activelle®)</brief_title>
  <acronym>TOTAL</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Double Dummy, Group-Comparative Trial to Compare the Effects of Livial® and Activelle ® on the Vaginal Bleeding Pattern, Vasomotor Complaints, Vaginal Atrophy, QoL and Sexual Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial is undertaken to compare the effects of Tibolone with a low-dose HRT
      regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For the bleeding evaluation, subject will be given a diary card to record the days on which no bleeding, vaginal spotting or bleeding occurs</measure>
    <time_frame>starting from baseline and during the whole trial period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hot flushes recorded on a daily diary card during the whole trial period.</measure>
    <time_frame>Entire trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A mammography to assess breast density and blood samples to determine the changes in endocrine parameters.</measure>
    <time_frame>screening and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A vaginal smear to assess the Vaginal Maturation Index and the Karyopycnotic Index results</measure>
    <time_frame>Baseline and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urogenital complaints assessed with the Local Urogenital Complaints Rating Scale.</measure>
    <time_frame>At baseline, week 12, week 24 and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life measured with the Women's Health Questionnaire 36-items (WHQ-36) the McCoy Female Sexuality Questionnaire-Short Form 9-items (MFSQ-SF) collecting prospectively medical resources utilization items</measure>
    <time_frame>At baseline and week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">570</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tibolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low-dose estradiol/noresterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tibolone</intervention_name>
    <description>uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Livial</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose estradiol/noresterone</intervention_name>
    <description>Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.
Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Activelle®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be healthy and postmenopausal women, &gt;= 45 and &lt; 65 years of age, with
             an intact uterus.

          -  Subjects must have been postmenopausal for less than 15 years.

          -  Body Mass Index &gt;18 and =&lt; 32 kg/m2.

          -  Voluntary written informed consent is required.

        Exclusion Criteria:

          -  Any unexplained abnormal uterine bleeding after the menopause.

          -  Double layer endometrial thickness = 6 mm as assessed by transvaginal ultrasonography.

          -  Treatment with oral estrogen and/or progestogen therapy within 4 weeks prior to
             screening, or treatment with transdermal therapy and local estrogen applications
             within 4 weeks prior to screening.

          -  Any previous or current unopposed estrogen administration, prior use of estrogen
             pellets or tamoxifen citrate (occasional use of estrogen-containing vaginal cream is
             allowed after the appropriate wash-out period is completed). Estrogen combined with
             sequential administration of progestogen should have been at least 10 days per 28 day
             cycle.

          -  The following wash-out periods apply:

               -  4 weeks for transdermal hormonal treatment, local estrogen applications or other
                  non-hormonal medication known to act on the relief of vasomotor symptoms (e.g.
                  clonidine)

               -  4 weeks for phytoestrogens, tibolone, intra-uterine or oral progestogen and oral
                  estrogen/progestogen therapy

               -  6 months for progestogen implants or injections and estrogen/progestogen
                  injectable therapy.

          -  Any subjects who are either using phytoestrogens, tibolone, intra-uterine or oral
             progestogen, progestogen implants or injections, estrogen/progestogen combination
             therapy or any other non-hormonal medication known to act on the relief of vasomotor
             symptoms and who have not observed the appropriate wash-out periods (see previous
             exclusion criteria).

          -  Any serious disease or disorder; or any endocrine disorder; (controlled
             hypo/hyperthyroidism and diabetes mellitus Type II is allowed).

          -  Diseases for which exogenous hormonal steroids are contraindicated.

          -  History or presence of any malignancy, except successfully treated nonmelanoma skin
             cancers.

          -  History or presence of cardiovascular or cerebrovascular conditions:

               -  thrombophlebitis, thrombosis or thromboembolic disorders.

          -  History or presence of liver, gallbladder (subjects who have had a cholecystectomy
             will not be excluded) or renal disease, epilepsy or classical migraine headaches.

          -  History or presence of clinically significant depression or other psychiatric
             disorders which, in the investigator's judgment, might compromise or confound the
             subject's participation in the trial.

          -  Uncontrolled high blood pressure: systolic pressure &gt; 170 mmHg and/or diastolic
             pressure &gt; 105 mmHg, measured after 5 minutes in a sitting position.

          -  Abnormal cervical Pap smear (corresponding to PAP = III, or LSIL, HSIL, ASCUS, AGCUS
             in the Bethesda classification)

          -  Abnormal, clinically significant results of the mammography.

          -  Presence of fibrocystic disease of the breast.

          -  Presence of otosclerosis.

          -  Known hypersensitivity to any of the ingredients of the trial medication.

          -  Any subjects using either steroids, drugs known to affect sexual functioning and mood
             (antidepressants, psychoactive drugs, sedatives, neuroleptics, narcotics,
             benzodiazepines), drugs know to interfere with the pharmacokinetics of the steroids
             (hydantoins, primidone, rifampicin, barbiturates, carbamazepine, griseofulvin,
             warfarin, ketoconazole, or products containing St. John's wort), or raloxifene
             hydrochloride. A wash-out period of 4 weeks will apply to subjects using these drugs.
             Sporadical use of benzodiazepines (twice or less a week) is allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2007</study_first_submitted>
  <study_first_submitted_qc>February 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2007</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Tibolone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

